Crenolanib

SKU: orb1305178

Description

Crenolanib (ARO 002) is an orally active, potent type III tyrosine kinase inhibitor targeting PDGFRα/β and FLT3 with low nanomolar IC50 values. It is widely used in preclinical research for studying acute myeloid leukemia (AML) and solid tumors, demonstrating activity in both in vitro cellular assays and in vivo xenograft models.

Research Area

Cardiovascular Research, Cell Biology, Signal Transduction

Key Properties

• CAS Number: 670220-88-9
• MW: 443.54
• Purity: 99.73%
• Formula: C₂₆H₂₉N₅O₂
• SMILES: CC1(COc2ccc3n(cnc3c2)-c2ccc3cccc(N4CCC(N)CC4)c3n2)COC1
• Target: PDGFR,Autophagy,FLT
• Solubility: DMSO:89 mg/mL (200.66 mM);Ethanol:7 mg/mL (15.78 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (4.51 mM)

Bioactivity

• Target IC50:
  PDGFRα:3.2 nmol/L (Kd)|PDGFRβ:2.1 nmol/L (Kd)|FLT3:0.74 nmol/L (Kd)
• In Vivo:
  Crenolanib significantly inhibited the growth of tumor mass, and the strongest inhibitory effect was observed with 20 mg/kg treatment. Crenolanib induced massive apoptosis in tumor cells. Furthermore, the dosage of crenolanib applied was well tolerated by recipient mice. No weight loss was observed during the course of treatment . Correlative data from an ongoing clinical trial demonstrate that acute myeloid leukemia patients can achieve sufficient levels of crenolanib to inhibit both FLT3/ITD and resistance-conferring FLT3/D835 mutants in vivo .
• In Vitro:
  Crenolanib is a specific and potent inhibitor of RTK. The Kd of crenolanib for the wild-type receptors PDGFRA, PDGFRB, and FLT3 was 3.2, 2.1, and 0.74 nmol/L, respectively. In EOL-1 cell line, Crenolanib potently inhibits the kinase activity of the fusion oncogene with IC50 values of 21 nmol/L. In addition, it potently inhibits the proliferation of EOL-1 cells (IC50: 0.2 pmol/L) . Crenolanib is a substrate of ABCB1, as evidenced by approximate five-fold resistance of ABCB1-overexpressing cells to crenolanib, reversal of this resistance by the ABCB1-specific inhibitor PSC-833 and stimulation of ABCB1 ATPase activity by crenolanib. In contrast, crenolanib was not a substrate of ABCG2 or ABCC1. Finally, incubation of the FLT3-ITD AML cell lines MV4-11 and MOLM-14 with crenolanib at a pharmacologically relevant concentration of 500 nM did not induce upregulation of ABCB1 cell surface expression . Crenolanib treatment abolished phosphorylation of FLT3 and ERK in HB119 cells, as well as in the AML-patient–derived FLT3–ITD+ cell line Molm14. Fifty nanomolar crenolanib suppressed phosphorylation of FLT3 in primary isolates, including in leukemic blasts from a quizartinib-resistant patient whose disease had evolved an FLT3–ITD/D835Y mutation .
• Cell Research:
  Cells were added to 96-well plates at densities of 20,000 cells per well and incubated with imatinib or crenolanib for 72 hours before measuring cellular proliferation using a 2,3-bis[2-methoxyl-4-nitro-5-sulfophenyl]-2H-tetrazolium-5-carboxanilide (XTT)–based assay .
• Animal Research:
  A549 cells were injected into the axillary regions of mice (2×10^6 cells/mouse). When the tumor volumes reached 70 mm^3, the mice were randomly allocated to the control group, low-dose crenolanib group (10 mg/kg), or high-dose crenolanib group (20 mg/kg) (n=6 per group). The vehicle for crenolanib treatment consists of 10% 1-methyl-2-pyrrolidinone and 90% polyethylene glycol 300. The tumor size and mouse body weight were measured every other day for about 2 weeks. The tumor volume was calculated as follows: (mm^3) = (width × width × length)/2. After treatment, the mice were euthanized using carbon dioxide, and the tumors were harvested and analyzed .

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Fms like tyrosine kinase 3, FLT3, Inhibitor, inhibit, Platelet-derived growth factor receptor, Crenolanib, CP 868596, CP868596, CP-868596, Cluster of differentiation antigen 135, CD135, Autophagy, ARO 002, ARO002, ARO-002, PDGFR, PDGFRα, PDGFRβ

Compound Identifiers

PubChem CID

10366136